On April 29, 2021, Mountain View, California-based startup Ceribell, Inc. announced the completion of a $53 million Series C financing,
Continue Reading Ceribell Announces Completion of $53 Million Series C Financing for Portable EEG that can Diagnose Seizures in Minutes
In Part I of this series providing a summary of the mRNA IP and competitive landscape through one year of
Continue Reading The mRNA Patent and Competitive Landscape: Pioneers, Litigation Outlook and Big Pharma’s Next Moves (Part III)
Capsida Biotherapeutics Inc.—a Thousand Oaks, CA-based emerging biotechnology company—recently emerged from stealth mode with $ 140 million in start-up capital
Continue Reading Capsida Biotherapeutics Debuts with $140 Million of Capital for its AAV Gene Therapies
In Part I of this three-part series, we focused on three mRNA technology market players: BioNTech, Moderna and CureVac.
Continue Reading The mRNA Patent and Competitive Landscape: Translate BIO; Arcturus; eTheRNA and Other Startups; and LNP Technology (Part II)
Shortly after we posted about Moderna, Inc.’s October 2020 pledge not to enforce its COVID-19-related patents during the pandemic, the
Continue Reading The mRNA Patent and Competitive Landscape Through One Year of the COVID-19 Pandemic–Part I
Bigfoot Biomedical®, a Milpitas, CA emerging company, recently announced that it has secured new financing of up to $57
Continue Reading Bigfoot Biomedical® Secures up to $57 Million in Financing from Madryn Asset Management
2021 started off well for Dana-Farber Cancer Institute, with the launch of its new venture fund, Binney Street Capital,
Continue Reading Dana-Farber Launches New Fund to Support Oncology Startups
On January 11, 2020, the Broad Institute, Verily Life Sciences, and Microsoft announced a strategic partnership to accelerate biomedical innovations
Continue Reading Microsoft Partners with Broad Institute and Verily to Expand Terra Platform for Biomedical Research
Earlier this week, Biogen and ViGeneron signed a global collaboration and licensing agreement to develop gene therapies for inherited eye
Continue Reading Biogen and ViGeneron to Collaborate on Ophthalmic Gene Therapy Development
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company
Continue Reading The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics